Heptares Therapeutics, a biotech spin-out from Cambridge University, has received $21m in a series B round that opens the door to clinical trials. Launched in 2007 after three years in incubation, the Welwyn Garden City-based spin-out is commercialising treatments for schizophrenia and Alzheimer’s developed at Cambridge’s Medical Research Council (MRC) Laboratory of Molecular Biology, which…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
